764 related articles for article (PubMed ID: 33822361)
1. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.
Kadali RAK; Janagama R; Peruru S; Gajula V; Madathala RR; Chennaiahgari N; Malayala SV
J Med Virol; 2021 Jul; 93(7):4420-4429. PubMed ID: 33822361
[TBL] [Abstract][Full Text] [Related]
2. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers.
Kadali RAK; Janagama R; Peruru S; Malayala SV
Int J Infect Dis; 2021 May; 106():376-381. PubMed ID: 33866000
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
5. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran.
Zare H; Rezapour H; Mahmoodzadeh S; Fereidouni M
Int Immunopharmacol; 2021 Dec; 101(Pt B):108351. PubMed ID: 34801416
[TBL] [Abstract][Full Text] [Related]
7. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees.
Jacobson MA; Zakaria A; Maung Z; Hart C; McCalmont TH; Fassett M; Amerson E
Clin Infect Dis; 2022 Mar; 74(4):591-596. PubMed ID: 34086881
[TBL] [Abstract][Full Text] [Related]
8. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
Lee YW; Lim SY; Lee JH; Lim JS; Kim M; Kwon S; Joo J; Kwak SH; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH; Bae S
J Korean Med Sci; 2021 May; 36(21):e153. PubMed ID: 34060261
[TBL] [Abstract][Full Text] [Related]
9. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
[TBL] [Abstract][Full Text] [Related]
10. Sick leave request following anti-COVID-19 vaccine administration is low among healthcare workers: results from a retrospective cross-sectional monocentric study.
Schianchi A; Ughi N; Cassano G; Del Gaudio F; Dicuonzo A; Scaglione F; Alberti PM; Rossetti C; Micheloni G; Zoppini L; Bellavia G; Giroldi S; Moreno M; Russo A; Bosio M; Epis OM
Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7218-7222. PubMed ID: 34919220
[TBL] [Abstract][Full Text] [Related]
11. Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals.
Melanson SEF; Zhao Z; Kumanovics A; Love T; Meng QH; Wu AHB; Apple F; Ondracek CR; Schulz KM; Wiencek JR; Koch D; Christenson R; Zhang YV
Front Public Health; 2022; 10():975781. PubMed ID: 36238255
[TBL] [Abstract][Full Text] [Related]
12. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Anderson EJ; Rouphael NG; Widge AT; Jackson LA; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Corbett KS; Swanson PA; Padilla M; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Martinez DR; Baric R; Buchanan W; Luke CJ; Phadke VK; Rostad CA; Ledgerwood JE; Graham BS; Beigel JH;
N Engl J Med; 2020 Dec; 383(25):2427-2438. PubMed ID: 32991794
[TBL] [Abstract][Full Text] [Related]
13. Effect of a hospital-wide campaign on COVID-19 vaccination uptake among healthcare workers in the context of raised concerns for life-threatening side effects.
Kim MH; Son NH; Park YS; Lee JH; Kim DA; Kim YC
PLoS One; 2021; 16(10):e0258236. PubMed ID: 34597333
[TBL] [Abstract][Full Text] [Related]
14. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
[TBL] [Abstract][Full Text] [Related]
15. Safety of COVID-19 vaccines.
Al Khames Aga QA; Alkhaffaf WH; Hatem TH; Nassir KF; Batineh Y; Dahham AT; Shaban D; Al Khames Aga LA; Agha MYR; Traqchi M
J Med Virol; 2021 Dec; 93(12):6588-6594. PubMed ID: 34270094
[TBL] [Abstract][Full Text] [Related]
16. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.
Johnston MS; Galan A; Watsky KL; Little AJ
JAMA Dermatol; 2021 Jun; 157(6):716-720. PubMed ID: 33978670
[TBL] [Abstract][Full Text] [Related]
17. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.
Kitagawa H; Kaiki Y; Sugiyama A; Nagashima S; Kurisu A; Nomura T; Omori K; Akita T; Shigemoto N; Tanaka J; Ohge H
J Infect Chemother; 2022 Apr; 28(4):576-581. PubMed ID: 35058126
[TBL] [Abstract][Full Text] [Related]
18. Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran.
Babamahmoodi F; Saeedi M; Alizadeh-Navaei R; Hedayatizadeh-Omran A; Mousavi SA; Ovaise G; Kordi S; Akbari Z; Azordeh M; Ahangarkani F; Alikhani A
Sci Rep; 2021 Nov; 11(1):21464. PubMed ID: 34728696
[TBL] [Abstract][Full Text] [Related]
19. Side effects of messenger RNA vaccines and prior history of COVID-19, a cross-sectional study.
Kadali RAK; Janagama R; Yedlapati SH; Kanike N; Gajula V; Madathala RR; Poddar S; Sukka N; Jogu HR; Racherla S; Shah I
Am J Infect Control; 2022 Jan; 50(1):8-14. PubMed ID: 34718069
[TBL] [Abstract][Full Text] [Related]
20. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
